The headline may refer to Nature’s Toolbox (NTx), which announced a $47.5 million Series B financing in November 2023. The available search results do not confirm that this is the exact article you mean.
NTx develops NTxscribe, a cell-free, continuous-flow platform for making RNA, including mRNA. The company said the funding would advance its biomanufacturing platforms.
The company positioned its approach as a way to make RNA production more scalable and accessible for therapeutic development, vaccines, and personalized medicine. RA Capital Management led the round and said its managing partner would join NTx’s board.
Because the headline you shared says $47 million and may be from a different, newer report, the company and details should be treated as unconfirmed without the article link or publication date.
Sources:
Biotech Funding and Partnerships Highlight AI Advancements
Fathom Therapeutics Raises $47M Series A for AI-Driven Drug Design
NTx Raises $47.5 Million to Advance Next-Generation ... - BioP2P
Primrose Bio Raises Growth Capital Led by Signet Healthcare Partners
Drug Discovery and Delivery Startups funded by ...
Checking if the site connection is secure
Biotech VC Funding Tracker 2026